Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 8/20 | 0.64 |
| ▸ | CDK7 | P50613 | 4/20 | 0.64 |
| ▸ | KDR | P35968 | 11/20 | 0.62 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13701571 | 0.78 | CHEK1 (1.00) | CHEK1CDK7KDRABL1LCK | |
| SCHEMBL4301049 | 0.77 | CHEK1 (0.61) | CHEK1CDK7KDR | |
| SCHEMBL7237397 | 0.77 | KDR (1.00) | CHEK1CDK7KDRABL1LCK | |
| SCHEMBL4292030 | 0.76 | CHEK1 (1.00) | CHEK1CDK7KDR | |
| SCHEMBL4297185 | 0.76 | CHEK1 (0.78) | CHEK1CDK7KDR | |
| SCHEMBL13701572 | 0.75 | CHEK1 (0.68) | CHEK1CDK7KDRLCK | |
| SCHEMBL4301046 | 0.73 | CHEK1 (0.72) | CHEK1CDK7KDR | |
| SCHEMBL4297337 | 0.73 | CHEK1 (0.72) | CHEK1CDK7KDR | |
| SCHEMBL22917459 | 0.72 | KDR (0.62) | CDK7KDRABL1LCKCSF1R | |
| SCHEMBL29539891 | 0.72 | KDR (0.62) | CDK7KDRABL1LCKCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233896-A1 | Inhibitors of checkpoint kinases | MERCK SHARP & DOHME CORP. | 2009-09-17 | — | — | US | disclosed |
| US-20090233896-A1 | Inhibitors of checkpoint kinases | MERCK SHARP & DOHME CORP. | 2009-09-17 | — | — | US | disclosed |
| US-20090233896-A1 | Inhibitors of checkpoint kinases | MERCK SHARP & DOHME CORP. | 2009-09-17 | — | — | US | disclosed |
| EP-1893607-A2 | INHIBITORS OF CHECKPOINT KINASES | Merck & Co., Inc. (US) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006135604-A2 | INHIBITORS OF CHECKPOINT KINASES | MERCK & CO., INC. (US) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233896-A1 | Inhibitors of checkpoint kinases | CHEK1, CHEK2, PLK1 | CHEK1 1/4885CDK7 39/4885KDR 3027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.